| This week's sponsor is Premier Research. | | | Rare Oncology Drug Advances. What's In It For You?
Take a look at how new drug development processes and regulatory pathways are helping speed development of novel therapies, including adaptive design strategies, endpoint selection, and effectively using biomarkers. Download our latest white paper now.
Premier Research. It's what we do. Best. |
Featured Story | | | Thursday, June 15, 2017 J&J has unveiled another clutch of deals and collaborations with industry and academia, as it also shares its molecular library to help fight neglected diseases. |
|
|
| This week's sponsor is Medpace. | | | |
Top Stories Thursday, June 15, 2017 Novartis and Verily have helped Medicxi raise $300 million (€268 million) to invest in late-stage drug developers. The fund sees Medicxi move beyond its original focus on early-stage biotechs to give European companies with drugs in phase 2 and beyond an alternative to selling up or partnering. Wednesday, June 14, 2017 LifeArc has set up a seed fund to invest in early preclinical projects that are overlooked because of the high risk of failure at that stage of R&D. The British medical research charity, formerly known as MRC Technology, sees the fund filling a perceived gap in the commercial investment landscape. Monday, June 12, 2017 “Patient centricity must be grounded in an engagement approach for the patients … ” Jonathan Zung, PhD, Covance. How do clinical research organizations (CROs) respond and support this increasing focus on patient-centric practices? Thursday, June 15, 2017 Pennsylvania biotech Ocugen has raised $7.5 million in a series B round as it fixes its sights on advancing a trio of eye disease treatments into clinical trials. Thursday, June 15, 2017 LabConnect has received a healthy $24.5 million in its first equity investment as it looks to push on with its clinical trial service offerings. Wednesday, June 14, 2017 Regulus Therapeutics has been suffering with its pipeline since its lead candidate RG-101 was put on clinical hold by the FDA last year. Now, with that candidate officially off the run, probably hoping to help turn things around, the microRNA biotech tapped the help of CRO Aptuit. Wednesday, June 14, 2017 Most people of normal weight don’t crave a cheeseburger right after they eat a full meal. But some people who struggle with obesity are still just as ravenous after they’ve chowed down as they were before. Now scientists at Beth Israel Deaconess Medical Center believe they’ve discovered why the process of feeling too full to eat any more goes awry in some people. Thursday, June 15, 2017 Having seen Zika’s devastating effects reach Florida residents, a bipartisan group of lawmakers in the state is urging the Army to pump the brakes on its exclusive vaccine license to Sanofi. | This week's sponsor is Cmed. | | | |
| | | OPKO Health has had a deeper look at the numbers and puts the blame for the fact that its growth hormone deficiency candidate didn't hit its targets last year on "outliers," and says when excluding those, things look brighter. Statement Selecta Biosciences announced positive data out from its ongoing phase 2 test for lead candidate SEL-212 in severe gout and will now prepare for phase 3 next year. Release CTI BioPharma has been given a $10 million sales milestone bonus from Teva for blood cancer med Trisenox (arsenic trioxide). Statement | |
|
Resources Presented by: Veeva Hear three innovative leaders explain how regulatory can “go digital” in their operations by leveraging the data-handling capabilities in their RIM systems. Sponsored By: Envigo Discover the factors that contribute to differential radiation sensitivity between the Rag2 and SCID models. Sponsored by Envigo Performing a sophisticated surgery to create a myocardial infarction model. Join us on June 7th at 11:00 AM EDT. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Sponsored By: HealthCore Gain critical insights into how to design and implement pragmatic trials and generate relevant, high-level real-world evidence. Learn when to conduct PTs, design considerations, ethical regulatory issues — and more. Sponsored By: Veeva Join this global webinar to learn a new approach for demonstrating medical affairs' impact with better metrics - beyond reach and frequency, enabling launch success and better engagement with strategic KOL insights, and increasing your organization's share of voice in the healthcare landscape. Sponsored By: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Sponsored By: DocuSign The patients who rely on your scientific leadership are expecting more. Sponsored By: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. FierceBiotech Executive Breakfast- Tackling the Drug Price Problem: A Town Hall Debate June 21, 2017 | San Diego, CA Drug Development Boot Camp® 2017 November 15-16, 2017 | Boston, MA FierceBiotech 2nd Drug Development Forum September 25-27, 2017 | Boston, MA 2017 BIO International Convention: The Largest Global Biotech Partnering Event of the Year June 19-22 | San Diego, CA Join 1,000 Diagnostics Professionals at Next Generation Dx Summit August 15-18, 2017 | Washington, DC |
